Audit: QRS - Bifidobacterium infantis for Health & Longevity
Audit conducted on 04/09/2026 06:04 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to ER text: protocol cells to ER lines 320/326/330, time cells to ER lines 160/172/370, benefits/risks to the ER tier headings, gates to ER lines 280–302, monitoring table and qualitative list to ER lines 396–413. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing is carried through, e.g. marker_4_target keeps “No established target; track change from the individual’s own baseline” verbatim from ER line 401. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain absolute and interactions remain cautions, matching the ER’s own labelling; the at-a-glance “Confirmed serious harm is limited to…” matches ER line 437 without widening or narrowing it. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No Benefit-Modifying or Risk-Modifying Factor appears in the gates; the immunosuppressant/chemotherapy item sits under Contraindications because ER line 284 labels it “Absolute contraindication during active therapy”. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, citations, expert names, NCT identifiers, or brand names at all. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present; ER attributions such as the 2023 FDA warning and the Whorwell trial were stripped rather than restated. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | The sheet reproduces the ER’s measured, sceptical register, including the strain-reassignment caveat and the company-funding note. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Precise dosing, timing, marker targets and a cadence give the reader an executable plan while the evidence limits are stated plainly. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is presented as findings and observed ranges, not as orders; no imperative instruction to the reader appears. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Monitoring targets and gate items are stated as facts; no prescriptive or diagnostic phrasing is used. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instances of “recommended”, “advised”, “should”, or “we suggest” in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns occur anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms that remain (APACHE II, Child-Pugh Class C, hs-CRP) are load-bearing decision-gate and biomarker terms carried verbatim from the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are single clauses; the ER’s 150-word monitoring paragraph is condensed to a 65-word cadence line. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text search: no “you”, “your”, or “yours” in the document. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | The protocol panel gives the adult regimen, and the monitoring card assumes a reader who will order laboratory tests and track markers. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | An 8–12 week continuous course, subspecies-level product verification, seven biomarkers and daily symptom scoring are all presented without hedging on effort or cost. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Subspecies-level stool sequencing and a glucose breath test are well beyond general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The at-a-glance states explicitly that the strong evidence is newborn evidence while adult evidence is thin, which is the ER’s central audience-relevant distinction. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal register throughout (“absolute neutrophil count”, “faecal calprotectin”, “colony-forming units”); “mental cloudiness” is the ER’s own term at lines 240 and 404. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate headings, tier labels and column headers match the template byte-for-byte. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | A set comparison of all data-qrs-var names shows zero template spans missing; the extra names are the expected numbered expansions of the template’s marker_#* and qualitative_item# repeat patterns. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A full diff against the template shows changes confined to checklist-addressed spans; CSS, structure, comments, footer and the website=”…” spans are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No section of the source ER is empty; the High-risk tier carries explanatory prose and is governed by item 13.5 instead. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1/2/3_label reproduce the ER bold labels “Standard adult protocol”, “Best time of day” and “Single versus split dosing” verbatim (ER lines 320, 326, 330); marker names reproduce the ER biomarker-table column verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Every label with an ER counterpart is verbatim; the Time-to-Effect cells carry aspect names because the ER supplies no per-aspect bold labels for that row. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | A Unicode range search returns no emoji; the ER’s 🟩/🟥/🟨 tier markers and ⚠️ conflict flags were stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every gate, tier and qualitative entry is a single line; the monitoring cadence and at-a-glance are condensed from much longer ER passages, and no template section was duplicated or extended. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: the comment opens immediately after the doctype on line 1 and precedes every other element. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Line 3 opens and line 13 closes the block; the descriptive text on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | It sits wholly inside an HTML comment and no metadata value is echoed anywhere in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values are trimmed; only duration: "00:02" is quoted, which is required because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: bifidobacterium_infantis_2026-0904-0315_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0904-0540, in the required format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no context-window or other qualifier appended. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s actual name on disk, bifidobacterium_infantis_2026-0904-0315_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; git_issue is an unquoted integer and git_user an unquoted scalar, as required. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Bifidobacterium infantis for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Bifidobacterium infantis for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/04/2026”, the correct MM/DD/YYYY rendering of 2026-0904. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header holds only the title and the template subline; the ER’s “Also known as” line and creation attribution were not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Its five sentences map one-to-one onto the four Conclusion paragraphs (ER lines 433–439): biology, the newborn/adult split, non-persistence, harm boundary, funding bias. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “milk-adapted… almost only in human milk” (line 433), “adult evidence is thin… strain later moved” (line 435), “Nothing persists after dosing stops” (line 435), harm boundary (line 437), “company-funded” (line 439). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “bowel injury”, “milk-adapted”, “immune-suppressed” and “company-funded” are all lay-readable, and the ER’s “necrotizing enterocolitis” was rendered as “bowel injury”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers of any kind appear in the at-a-glance text. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items originate in ER lines 278–302. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | The ER’s seven “Populations who should avoid” bullets plus the immunosuppressant/chemotherapy bullet that ER line 284 designates an absolute contraindication; nothing is missing and nothing extra was added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 542–549: eight well-formed <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No dashes remain; the FDA attribution (ER line 296) and the explanatory glosses after the em-dash in the APACHE II item (ER line 299) and on Child-Pugh (ER line 302) were stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “under 1000 g”, “below 500 per microlitre”, “APACHE II score of 8 or more”, “under 200 cm of residual small intestine”, “Class C”, “during active therapy” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication bullets. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER identifies eight such populations and the section is correspondingly populated, not empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items originate in ER lines 280–292. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Six of the ER’s seven interaction bullets appear; the immunosuppressant/chemotherapy bullet is correctly omitted here because it sits in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 557–562: six well-formed <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | All rationale was stripped, including the Elison et al. citation (ER line 288) and the “Other interventions —” dash prefix (ER line 292); no dash-trailing content remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every named-drug parenthetical is retained in full: the four antibiotics, the three proton pump inhibitors, the two oligosaccharides, and the five prebiotic/bifidogenic agents. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies six such interactions and the section is correspondingly populated, not empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from the ER Therapeutic Protocol bullets at lines 320, 326 and 330. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing relative to food, and single-versus-split dosing are the three decisions a reader must make before starting; the remaining ER bullets are modifiers or competing approaches rather than baseline actions. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well more than three actionable aspects and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry substantive ER-derived content; the CFU range, the with-food rule and the single-dose rationale each trace to a specific ER bullet. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Inflammatory markers at 6–8 weeks (ER line 160), coeliac symptoms at 3 weeks (ER line 172), and stool measures at 7–14 days, the ER’s own explicit “Time to effect” bullet (line 370). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | The two Medium-tier benefit outcomes lead, in the ER’s own Medium-tier order, followed by the stool readout, which carries no benefit tier. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three distinct time-to-effect aspects and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans are populated; each sub-line paraphrases its ER source closely (lines 160, 172, 370). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten entries correspond to the ten ER benefit headings at lines 142–202, in ER order within each tier. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated at lines 521–532. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER heading alone; the RR figures, confidence intervals, sponsor notes and mechanistic paragraphs were all dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers carry items in the ER, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven entries correspond to the ER risk headings at lines 226–264. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present at lines 574–583. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER heading alone; the mortality figures, case counts, FDA reference and ⚠️ Conflicted flags were dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks span; the ER’s glosses such as “(a build-up of poorly cleared acid)” were removed. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | ER line 222 states that no risk reaches High; line 574 accordingly carries an emptied risks_high span with style="display: none" and no empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table and cadence come from the ER Monitoring Protocol & Defining Success section at lines 394–404. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER biomarker rows appear in ER order with names, optimal ranges and rationales carried verbatim; the ER’s Context/Notes column was correctly not carried over. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 680 condenses ER line 394 into baseline, 4-week stool, 8–12-week inflammation, 6–12-month repeat, 4-week post-stop stool, plus the baseline-only and conditional-test rules. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | The six items come from the qualitative-marker list at ER lines 408–413. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are present and verbatim: bloating/distension, stool form and frequency, post-meal gas, mental clarity, skin itch and eczema activity, and daytime energy. |
Issues 04/09/2026 06:04
Pass rate 100.00%. No issues found.
Issues 04/09/2026 06:00
- 1.3 — At-a-glance overstates safety boundary:
at_a_glance(line 433) says “Serious harm is confined to extremely premature or severely immune-suppressed patients”, strengthening the ER Conclusion’s hedged “The confirmed serious harms are … alongside a warning drawn from a trial in critically ill patients” (ER line 437) and contradicting the QRS’s ownrisks_lowitem “harm when used in critically ill patients” (line 579).
Fixes 04/09/2026 06:00
- 1.3 — At-a-glance safety boundary re-hedged: Changed
at_a_glancefrom “Serious harm is confined to extremely premature or severely immune-suppressed patients” to “Confirmed serious harm is limited to extremely premature or severely immune-suppressed patients”, restoring the ER’s “confirmed” bound so the sentence no longer overstates the ER or contradicts therisks_lowentry on critically ill patients. At-a-glance remains within the 60-word budget at 58 words.
Issues 04/09/2026 05:54
- 1.1 — Cadence overstates baseline panel: [monitoring_cadence] (line 680) begins “Baseline for all markers”, but the ER’s glucose breath test is “Ordered only where bloating with mental cloudiness appears” (ER line 404) and is not part of the baseline panel listed at ER line 394.
- 8.5 — “During active therapy” qualifier dropped: The immunosuppressant/chemotherapy contraindication (line 549) omits the ER’s time-window scope; ER line 284 reads “Absolute contraindication during active therapy”.
- 11.4 — time_3_sub contradicts its own cell: [time_3_sub] (line 511) states “Eight weeks is the earliest reasonable judgement point for symptoms” under the label “Stool measures” with value “7–14 days”; the ER sentence supporting that value is “Stool measures shift within seven to fourteen days of daily dosing” (ER line 370).
Fixes 04/09/2026 05:54
- 1.1 — Cadence baseline scope corrected: Changed “Baseline for all markers” to “Baseline for inflammation, stool and immune-screening markers” and added that the glucose breath test is ordered only where bloating with mental cloudiness appears, matching the ER.
- 8.5 — Active-therapy qualifier restored: Appended “during active therapy” to the immunosuppressant and cytotoxic chemotherapy contraindication item, restoring the ER’s time-window scope.
- 11.4 — time_3_sub realigned with its cell: Replaced “Eight weeks is the earliest reasonable judgement point for symptoms” with “Stool measures shift within seven to fourteen days of daily dosing”, the ER sentence that supports the label and 7–14 day value.
Issues 04/09/2026 05:49
- 1.3 — Short bowel threshold narrowed: Line 546 renders the ER’s “short bowel syndrome, particularly with under 200 cm of residual small intestine” (ER line 300) as “Short bowel syndrome (under 200 cm of residual small intestine)”, converting an emphasis into a defining criterion and softening the contraindication for short bowel syndrome above 200 cm.
- 2.8 — Redundant time-to-effect subtext: Line 511’s time_3_sub opens by restating the cell’s own label and value (“Stool measures shift within seven to fourteen days of daily dosing”) before adding the eight-week judgement point, spending the sheet’s tightest cell on repetition.
Fixes 04/09/2026 05:49
- 1.3 — Short bowel threshold restored: Changed the contraindication at line 546 from “Short bowel syndrome (under 200 cm of residual small intestine)” to “Short bowel syndrome (especially under 200 cm of residual small intestine)”, restoring the ER’s “particularly” emphasis so the item no longer excludes short bowel syndrome above 200 cm.
- 2.8 — Redundant time-to-effect subtext trimmed: Cut the leading clause of time_3_sub, which restated the cell’s own label and value, leaving “Eight weeks is the earliest reasonable judgement point for symptoms”.
Issues 04/09/2026 05:43
- 4.2 / 4.3 — Contraindication label paraphrased: Contraindication item 8 (QRS line 549) reads “Active immunosuppressant therapy (tacrolimus, ciclosporin, mycophenolate, high-dose corticosteroids) or cytotoxic chemotherapy”, whereas the ER’s bold label at line 284 is “Immunosuppressants (tacrolimus, ciclosporin, mycophenolate, high-dose corticosteroids) and cytotoxic chemotherapy”; the head noun was reworded and the conjunction changed from “and” to “or”.
Fixes 04/09/2026 05:43
- 4.2 / 4.3 — Contraindication label paraphrased: Restored the ER’s bold label verbatim in contraindication item 8, changing “Active immunosuppressant therapy (…) or cytotoxic chemotherapy” to “Immunosuppressants (tacrolimus, ciclosporin, mycophenolate, high-dose corticosteroids) and cytotoxic chemotherapy”.